David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$862M |
| 2 |
Baidu
BIDU
|
+$752M |
| 3 |
Tencent Music
TME
|
+$426M |
| 4 |
Coca-Cola
KO
|
+$424M |
| 5 |
NVIDIA
NVDA
|
+$383M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$981M |
| 2 |
Wells Fargo
WFC
|
+$673M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$574M |
| 4 |
Moderna
MRNA
|
+$442M |
| 5 |
DuPont de Nemours
DD
|
+$415M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 30.1% |
| 2 | Technology | 16.45% |
| 3 | Consumer Discretionary | 10.49% |
| 4 | Communication Services | 9.04% |
| 5 | Healthcare | 8.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2101
PUT
Viatris
VTRS
$19.5B
| $3M | ﹤0.01% |
214,876
-547,620
| -72% | -$8.92M |
|
|
NXGN
2102
DELISTED
NextGen Healthcare, Inc. Common Stock
NXGN
| $3M | ﹤0.01% |
165,880
-117,459
| -41% | -$2.32M |
|
|
GTH
2103
DELISTED
Genetron Holdings Limited ADS
GTH
| $3M | ﹤0.01% |
46,564
+6,114
| +15% | +$420K |
|
|
EXK
2104
Endeavour Silver
EXK
$3.32B
| $3M | ﹤0.01% |
+604,324
| New | +$3.24M |
|
2105
CALL
Abbott
ABT
$194B
| $3M | ﹤0.01% |
25,000
-75,000
| -75% | -$8.89M |
|
2106
Marathon Petroleum
MPC
$101B
| $2.99M | ﹤0.01% |
55,896
+41,372
| +285% | +$2.09M |
|
2107
CALL
Ubiquiti
UI
$35.2B
| $2.98M | ﹤0.01% |
10,000
-74,700
| -88% | -$23.5M |
|
2108
OFG Bancorp
OFG
$2.2B
| $2.98M | ﹤0.01% |
131,819
-6,864
| -5% | -$136K |
|
|
PDOT.U
2109
DELISTED
Peridot Acquisition Corp. II Units, each consisting of one Class A ordinary share, and one-fifth of one redeemable warrant
PDOT.U
| $2.98M | ﹤0.01% |
+300,000
| New | +$2.98M |
|
2110
E.W. Scripps
SSP
$294M
| $2.97M | ﹤0.01% |
153,949
+23,955
| +18% | +$441K |
|
2111
J.M. Smucker
SJM
$14.3B
| $2.96M | ﹤0.01% |
23,437
-74,635
| -76% | -$8.81M |
|
2112
CALL
Sabre
SABR
$868M
| $2.96M | ﹤0.01% |
+200,000
| New | +$2.71M |
|
|
FTEV.U
2113
DELISTED
FinTech Evolution Acquisition Group Units, each consisting of one Class A Ordinary Share, and one-third of one redeemable warrant
FTEV.U
| $2.96M | ﹤0.01% |
+300,000
| New | +$3M |
|
2114
PUT
CoStar Group
CSGP
$13B
| $2.96M | ﹤0.01% |
+36,000
| New | +$3.11M |
|
|
SCS
2115
DELISTED
Steelcase
SCS
| $2.95M | ﹤0.01% |
205,020
-188,852
| -48% | -$2.68M |
|
2116
Vera Bradley
VRA
$95M
| $2.95M | ﹤0.01% |
291,901
-96,928
| -25% | -$912K |
|
2117
CALL
American Express
AXP
$225B
| $2.94M | ﹤0.01% |
20,800
-100,100
| -83% | -$13.2M |
|
2118
SiTime
SITM
$18B
| $2.94M | ﹤0.01% |
29,831
+3,801
| +15% | +$445K |
|
|
FVT
2119
DELISTED
Fortress Value Acquisition Corp. III
FVT
| $2.94M | ﹤0.01% |
+297,078
| New | +$2.97M |
|
2120
PetMed Express
PETS
$39M
| $2.94M | ﹤0.01% |
83,418
+76,510
| +1,108% | +$2.66M |
|
2121
Sixth Street Specialty
TSLX
$1.8B
| $2.93M | ﹤0.01% |
139,379
+62,838
| +82% | +$1.35M |
|
2122
Arrowhead Research
ARWR
$12.5B
| $2.93M | ﹤0.01% |
44,185
-44,414
| -50% | -$3.45M |
|
2123
PUT
QuidelOrtho
QDEL
$1.05B
| $2.93M | ﹤0.01% |
+22,900
| New | +$4.23M |
|
2124
PUT
Macerich
MAC
$6.84B
| $2.93M | ﹤0.01% |
+250,300
| New | +$3.35M |
|
2125
CryoPort
CYRX
$839M
| $2.93M | ﹤0.01% |
56,261
-270,710
| -83% | -$16.5M |
|
Similar funds
David Shaw's Q1 2021 Portfolio in Review
As of Q1 2021, David Shaw held 4,712 positions worth $104B, down 7.4% from $112B the previous quarter. Its ten largest holdings account for 9.9% of the portfolio.
David Shaw withdrew a net $10.4B in Q1 2021, closing 730 positions and reducing 1,773 holdings. Its most notable exit was AstraZeneca, an estimated $214M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 30% of assets, down from 35% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, David Shaw opened a new position in Baidu worth $627M.
- David Shaw's largest Q1 2021 buy was Baidu: 2,881,724 shares worth $627M.
- David Shaw added most to Tesla in Q1 2021, an estimated $862M increase.
- David Shaw's biggest Q1 2021 reduction was Amazon, cutting an estimated $981M.
- David Shaw fully exited AstraZeneca in Q1 2021, selling an estimated $214M.
- David Shaw's ten largest holdings make up 9.9% of its $104B portfolio in Q1 2021.
- David Shaw opened 825 new positions and closed 730 in Q1 2021.
- David Shaw's portfolio value fell 7.4% quarter-over-quarter to $104B.
Based on D.E. Shaw & Co's 13F filing for Q1 2021, filed 17 May 2021.